SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BriaCell Presents Biomarker Data Linking PD-L1 Changes to Outcomes

BriaCell Therapeutics presented pooled ESMO 2026 data indicating that changes in PD-L1 on circulating CAMLs after immunotherapy correlated with progression-free and overall survival in metastatic breast cancer. Its pivotal Phase 3 trial of Bria-IMT plus a checkpoint inhibitor is ongoing.

BCT
SquawkNews Desk

Related stories

Microsoft Restores Services After Hourslong Global Outage Microsoft said services were fully restored after an hourslong global outage. M impact | EQUITY | Nov 14, 2026, 09:12 AM UTC Rs.4K cr Ramayana movie VFX maker parent Prime Focus shares in focus after 14x profit jump in Q2; stock up 61% in a year New Delhi, Nov. 14 -- Prime Focus Ltd, the parent company of visual effects and animation studio DNEG, is likely to remain in focus on Monday after announcing its September-quarter L impact | EQUITY | Nov 14, 2026, 09:04 AM UTC Microsoft Restores Service After Global Outage Microsoft said its disruption to central cloud services is over. M impact | EQUITY | Nov 14, 2026, 09:01 AM UTC US Flights to Resume After Air Traffic Network Failure US flights are set to resume after an air traffic network failure disrupted operations. M impact | EQUITY | Nov 14, 2026, 08:06 AM UTC UniCredit Raises $3.5 Billion M impact | EQUITY | Nov 14, 2026, 08:03 AM UTC AMAT Shares Fall 2.58% as Headline Cites Record Q4 Revenue The headline also says 2027 demand is seen above 30%, but provides no further context. M impact | EQUITY | Nov 14, 2026, 08:02 AM UTC